CELC NASDAQ
Celcuity Inc.
1W: +15.2%
1M: -17.2%
3M: -20.2%
YTD: -34.6%
1Y: -6.8%
3Y: +556.7%
5Y: +273.0%
$68.11
+2.31 (+3.51%)
Weekly Expected Move ±8.8%
$54
$59
$65
$71
$77
Credit Risk of going bust: higher than 68% of companies Debt: 19.0% of company value Bonds: $29.4M held by 33 funds → details ▾
Of US companies ranked in the middle of the pack, about 1 in 580 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $1.92 (down 97%), Celcuity Inc. would be worth roughly what it owes.
Total debt $754.4M against a stock market value of $3.22B.
Distance to default 3.58 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $377.1M (short-term plus half of long-term), stock volatility 65.8%; Altman Z'' 1.75. A ranking and a back-test, not a forecast.
Bond figures are fund-reported marks (SEC N-PORT) as of Jul 2026. How these are computed.
If the stock fell to about $1.92 (down 97%), Celcuity Inc. would be worth roughly what it owes.
Total debt $754.4M against a stock market value of $3.22B.
Distance to default 3.58 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $377.1M (short-term plus half of long-term), stock volatility 65.8%; Altman Z'' 1.75. A ranking and a back-test, not a forecast.
Bond figures are fund-reported marks (SEC N-PORT) as of Jul 2026. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Moderate
50
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$3.2B
52W Range53.54-151.02
Volume1,866,245
Avg Volume1,345,468
Beta0.16
Dividend—
Analyst Ratings
Company Info
CEOBrian F. Sullivan
Employees155
SectorHealthcare
IndustryBiotechnology
IPO Date2017-09-19
Websitecelcuity.com
2800 Campus Drive
Minneapolis, MN 55441
US
Minneapolis, MN 55441
US
763 392 0767
About Celcuity Inc.
Celcuity, Inc. operates as a cellular analysis company. The company discovers new cancer sub-types and commercializing diagnostic tests designed to improve the clinical outcomes of cancer patients treated with targeted therapies. The firm's proprietary CELx diagnostic platform is the commercially ready technology that uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the targeted therapy that treats it. The company was founded by Brian F. Sullivan and Lance G. Laing in January 2012 and is headquartered in Minneapolis, MN.
Latest News
Celcuity says Revtorpyk boosts progression-free survival in breast cancer
1,290,466 Celcuity, Inc. $CELC Shares Bought by Assenagon Asset Management S.A.
New Strong Sell Stocks for October 14th
Seeking Alpha’s Quant Spotlight: Highest and lowest rated healthcare stocks ahead of Q3
12,476 Celcuity, Inc. $CELC Shares Purchased by Envestnet Asset Management Inc.
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| GRYSKA DAVID W | A-Award | 893 | — | 2026-10-01 |
| GRYSKA DAVID W | 0 | — | 2026-10-01 | |
| Laing Lance G. | A-Award | 20,000 | — | 2026-08-14 |
| Laing Lance G. | A-Award | 10,000 | — | 2026-08-14 |
| Sullivan Brian F. | A-Award | 80,000 | — | 2026-08-14 |